{"id":389105,"date":"2023-12-19T00:00:00","date_gmt":"2023-12-19T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0001-2023-biopharma-breast-cancer-disease-landscape-forecast-g7-2023\/"},"modified":"2026-03-31T10:31:29","modified_gmt":"2026-03-31T10:31:29","slug":"dlsfon0001-2023-biopharma-breast-cancer-disease-landscape-forecast-g7-2023","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0001-2023-biopharma-breast-cancer-disease-landscape-forecast-g7-2023\/","title":{"rendered":"Breast Cancer | Disease Landscape &#038; Forecast | G7 | 2023"},"content":{"rendered":"<p>The treatment of breast cancer is associated with strong commercial opportunity because of the disease\u2019s high incidence, long treatment durations, and multiple lines of therapy. The CDK4\/6 inhibitors (Pfizer\u2019s Ibrance, Novartis\u2019s Kisqali, and Eli Lilly\u2019s Verzenio\/Verzenios) are entrenched in the treatment of HR-positive \/ HER2-negative disease, a trend that will continue through 2032. Current treatment options for HER2-positive breast cancer have expanded, owing to the launch of novel HER2-targeting agents (Daiichi Sankyo \/ AstraZeneca\u2019s Enhertu, Seagen \/ Pfizer\u2019s Tukysa, and MacroGenics\u2019 Margenza), sales of which will offset the entry of generics and biosimilars. In triple-negative breast cancer, the approvals of PARP inhibitors (AstraZeneca \/ Merck &#038; Co.\u2019s Lynparza, Pfizer\u2019s Talzenna), immune checkpoint inhibitors (Merck &#038; Co.\u2019s Keytruda), and TROP2-targeted agents (Gilead\u2019s Trodelvy) are diversifying therapy options for patients. Enhertu\u2019s approval in 2022 for HER2-low disease, a new subset of breast cancer, will further reshape the treatment landscape.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul>\n<li>What is the size of clinically and commercially relevant drug-treatable breast cancer populations, and how will drug-treatment rates change over time?<\/li>\n<li>What is the expected market impact of recent drug approvals, such as Trodelvy, Keytruda, Piqray, Enhertu, and Orserdu, on the various subpopulations of breast cancer?<\/li>\n<li>Which are the most promising agents in the pipeline, and how will they shape the future of the breast cancer therapy market?<\/li>\n<li>Which key drivers and constraints will affect the breast cancer therapy market over the forecast period?<\/li>\n<\/ul>\n<p><strong>CONTENT HIGHLIGHTS<\/strong><\/p>\n<ul>\n<li>Geographies: United States, EU5, Japan.<\/li>\n<li>Primary research: 18 country-specific interviews with thought-leading medical oncologists supported by survey data collected for this and other Clarivate research.<\/li>\n<li>Epidemiology: Incidence of breast cancer by country, segmented by HR and HER2 status, staging, and line of therapy.<\/li>\n<li>Forecast: 10-year, annualized, drug-level sales and patient share of key breast cancer therapies through 2032, segmented by brands \/ biosimilars \/ generics and market-relevant drug-treatable populations.<\/li>\n<li>Emerging therapies: Phase 3\/PR: 20 drugs; coverage of select Phase 1 and 2 products.<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p><em>Disease Landscape &#038; Forecast<\/em> provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n<p><strong>SOLUTION ENHANCEMENT<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.<\/p>\n<p>Disease Landscape &#038; Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.<\/p>\n","protected":false},"template":"","class_list":["post-389105","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-breast-cancer","biopharma-date-975"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389105","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389105\/revisions"}],"predecessor-version":[{"id":576014,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389105\/revisions\/576014"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=389105"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}